Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.6775 on Friday. Threshold Pharmaceuticals has a 1-year low of $0.21 and a 1-year high of $4.44. The stock’s 50 day moving average is $1.06 and its 200-day moving average is $0.62. The company has a market capitalization of $48.45 million, a P/E ratio of 1.1444 and a beta of 3.98.
Threshold Pharmaceuticals (NASDAQ:THLD) last posted its quarterly earnings results on Monday, August 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.10). On average, analysts expect that Threshold Pharmaceuticals will post ($0.38) earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its position in shares of Threshold Pharmaceuticals by 55.5% in the first quarter. Renaissance Technologies LLC now owns 1,016,764 shares of the biotechnology company’s stock worth $468,000 after buying an additional 363,100 shares during the period. Adage Capital Partners GP L.L.C. increased its position in shares of Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock worth $1,610,000 after buying an additional 500,000 shares during the period. Oxford Asset Management increased its position in shares of Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock worth $129,000 after buying an additional 178,602 shares during the period. First Eagle Investment Management LLC purchased a new position in shares of Threshold Pharmaceuticals during the second quarter worth approximately $2,033,000. Finally, Deerfield Management Co. purchased a new position in shares of Threshold Pharmaceuticals during the second quarter worth approximately $1,641,000. 28.22% of the stock is currently owned by hedge funds and other institutional investors.
Threshold Pharmaceuticals Company Profile
Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.